EGFR-activating mutations and treatment with tyrosine-kinase inhibitors (TKI) to revert poor-prognosis (PP) associated with liver metastases (LM) in stage IV non-small cell lung cancer (NSCLC) patients (pts).
Eduardo Castanon
No relevant relationships to disclose
Maria D. Lozano
No relevant relationships to disclose
Juan Pablo Fusco
No relevant relationships to disclose
Estefania Arevalo
No relevant relationships to disclose
Omar Esteban Carranza
No relevant relationships to disclose
José María López-Picazo
No relevant relationships to disclose
Jose Luis Perez-Gracia
No relevant relationships to disclose
Alfonso Gurpide
No relevant relationships to disclose
Ignacio Gil-Bazo
No relevant relationships to disclose